Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Diabetes Health Center

Font Size

Delaying Type 1 Diabetes

B-Lymphocytes May Hold Key to Delaying Type 1 Diabetes
WebMD Health News
Reviewed by Louise Chang, MD

Nov. 25, 2009 -- Researchers may have found a new way to delay, or perhaps prevent, type 1 diabetes.

Type 1 diabetes usually begins early in life, when the T-lymphocyte arm of the immune system attacks insulin-making beta cells in the pancreas. Researchers hoping to slow or stop this process have targeted T lymphocytes or T cells.

But recent research suggests that B lymphocytes play a role in T-lymphocyte immunity. In non-obese mice with diabetes, depleting B cells inhibits the disease. Can it work in humans?

Yes, find Indiana University's Mark D. Pescovitz, MD and a team of diabetes experts from 12 U.S. and Canadian diabetes centers.

Pescovitz and colleagues report data from 78 newly diagnosed type 1 diabetes patients who completed a double-blind, randomized, placebo-controlled trial of the arthritis and cancer drug Rituxan. Rituxan, a man-made antibody, attacks B cells via the CD-20 molecule on the surface of the cells.

Patients got a single four-infusion course of Rituxan and then were followed closely for a year. Over the course of the year, patients who received the drug had slower loss of insulin-producing cells as measured by C peptide (during insulin production in the pancreas, proinsulin molecules are split into insulin and C-peptide).

Unfortunately, a single course of Rituxan wasn't enough to stop diabetes. After a year, B cells in treated patients increased to 69% of their original values.

But the study does show that a treatment targeting B cells can preserve beta-cell function in early type 1 diabetes.

"It is unlikely that treatment with [Rituxan] as administered in this study would be optimal," Pescovitz and colleagues note. "Given our results, we believe that other anti-B-lymphocyte agents should be tested -- for example, anti-CD20 antibodies."

The study was funded by the National Institutes of Health, the Juvenile Diabetes Research Foundation, and the American Diabetes Association. Pescovitz and colleagues report their findings in the Nov. 26 issue of the New England Journal of Medicine.

Today on WebMD

Diabetic tools
Symptoms, diagnosis, treatment, and more.
woman flexing muscles
10 strength training exercises.
Blood sugar test
12 practical tips.
Tom Hanks
Stars living with type 1 or type 2.
kenneth fujioka, md
Can Vinegar Treat Diabetes
Middle aged person
Home Healthcare

Prediabetes How to Prevent Type 2 Diabetes
type 2 diabetes
food fitness planner